EINDHOVEN, The Netherlands, July 28, 2026
Xeltis has raised an additional €20.5 million in funding to accelerate the development and commercialization of its aXess™ vascular access technology while advancing its broader regenerative implant pipeline. The financing round was led by new investor Horizon 3 Healthcare and included continued participation from the European Innovation Council (EIC), Invest-NL, VI Partners, EQT Life Sciences, DaVita, and other existing shareholders. The latest investment builds on the €50 million secured by the company in 2025 and provides additional financial resources to support clinical development, regulatory activities, manufacturing expansion, and commercial execution. The successful fundraising demonstrates strong investor confidence in Xeltis’ long-term strategy and its regenerative implant technology designed to create living blood vessels for patients requiring vascular access and cardiovascular treatments.
Capital to Drive FDA Submission and Global Commercial Growth
The proceeds from the financing will be used to complete the ongoing U.S. pivotal clinical trial of aXess™, the company’s lead product for hemodialysis vascular access, while supporting preparations for FDA submission and a future U.S. commercial launch. In addition, the investment will fund the continued European commercial rollout of aXess™, expand the company’s manufacturing capabilities, and advance its XABG and XPAD clinical development programs targeting additional vascular and cardiovascular applications. Chief Executive Officer Eliane Schutte said the new capital will allow Xeltis to expand patient access to its regenerative vascular technology across Europe while preparing for entry into the U.S. market. She also welcomed Horizon 3 Healthcare as a new lead investor and thanked existing shareholders for their continued support as the company advances multiple clinical and commercial milestones
Investor Confidence Reinforced by Commercial Progress
The financing follows Xeltis’ recent announcement that it successfully treated its first commercial patient in Germany, marking an important milestone after the European launch of aXess™ following CE Mark approval. At the same time, enrollment in the company’s U.S. pivotal trial has progressed beyond 50%, bringing the program closer to regulatory submission in the United States. Investors participating in the financing highlighted the company’s compelling clinical progress and the significant opportunity to improve treatment options for patients undergoing hemodialysis. Horizon 3 Healthcare noted that the clinical data generated to date supports the potential of aXess™ to transform vascular access, while Invest-NL emphasized the importance of supporting the company’s commercial expansion. The European Innovation Council also reaffirmed its commitment to backing breakthrough healthcare technologies capable of transforming patient care across Europe.
Advertisement
Funding Positions Xeltis for Next Phase of Growth
The latest investment strengthens Xeltis’ financial position as it enters a critical phase of clinical, regulatory, and commercial execution. The company’s proprietary Restorex® platform enables implants to gradually regenerate into a patient’s own living tissue, offering a differentiated approach to vascular repair and replacement. Beyond aXess™, Xeltis continues to expand its pipeline through the XABG and XPAD programs, targeting additional cardiovascular and vascular indications with the same regenerative technology. With more than €70 million secured over the past two years, continued support from leading healthcare investors, and advancing regulatory milestones in both Europe and the United States, Xeltis is well positioned to accelerate innovation, expand commercialization efforts, and deliver next-generation regenerative vascular solutions to patients worldwide.
Source: Xeltis press release
